News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Decision Resources Group Release: Biosimilar Versions of TNF-alpha Inhibitors and Pegylated IFN-alpha Agents Will Save Healthcare Systems $5.3 Billion in 2020


10/3/2011 9:56:31 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar versions of tumor necrosis factor (TNF)-alpha inhibitors and pegylated interferon (IFN)-alpha agents will save healthcare systems in the United States and EU5 (France, Germany, Italy, Spain and the United Kingdom) $5.3 billion in 2020. According to Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, biosimilar TNF-alpha inhibitors will contribute the majority of cost savings.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES